Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Connect Biopharma Holdings Limited - Ordinary Shares (NQ:CNTB)

0.9484 -0.1516 (-13.78%)
Delayed Quote Updated: 2:45 PM EDT, Oct 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,266,303
Open 1.115
Bid (Size) 0.9451 (100)
Ask (Size) 0.9516 (500)
Prev. Close 1.100
Today's Range 0.9433 - 1.120
52wk Range 0.9800 - 3.820
Shares Outstanding 55,041,247
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Top movers analysis one hour before the close of the markets on 2026-09-30: top gainers and losers in today's session. ↗
Via Chartmill
Discover the most active stocks in Wednesday's session. ↗
Via Chartmill

Performance

YTD
-62.4%
-62.4%
1 Month
-56.9%
-56.9%
3 Month
-60.3%
-60.3%
6 Month
-65.1%
-65.1%
1 Year
-37.2%
-37.2%

More News

Read More
Let's take a look at the stocks that are in motion in today's session. ↗
Via Chartmill
Which stocks are gapping on Wednesday? ↗
Via Chartmill
Wednesday's pre-market session: top gainers and losers ↗
Via Chartmill
News headline image
Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation
From Connect Biopharma Holdings Limited
Via GlobeNewswire
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
Via Chartmill
Keep an eye on the top gainers and losers in Tuesday's session. ↗
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
What's going on in today's pre-market session ↗
Via Chartmill
News headline image
Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adult and Adolescent Participants with Asthma and Type 2 Inflammation
From Connect Biopharma Holdings Limited
Via GlobeNewswire
These stocks are moving in today's after hours session ↗
Via Chartmill
News headline image
Connect Biopharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
Connect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business Update
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
Connect Biopharma Announces Completion of Enrollment of Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
Connect Biopharma Touts Rademikibart’s Edge as SEABREEZE Data Looms in 2026 ↗
Via MarketBeat
News headline image
Connect Biopharma to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
Connect Biopharma Announces Enrollment in Phase 2 Seabreeze STAT Studies Will Continue as Planned Following Pre-Specified Interim Analysis
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
RedChip's April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms
Via ACCESS Newswire
Wondering what's happening in today's after-hours session? ↗
Via Chartmill
News headline image
Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
Connect Biopharma Announces $20.2 Million Private Placement Financing
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
Connect Biopharma Announces Positive Topline Data from its Phase 1 Study of Intravenous (IV) Rademikibart in Patients with Asthma or COPD
From Connect Biopharma Holdings Limited
Via GlobeNewswire

Frequently Asked Questions

Is Connect Biopharma Holdings Limited - Ordinary Shares publicly traded?
Yes, Connect Biopharma Holdings Limited - Ordinary Shares is publicly traded.
What exchange does Connect Biopharma Holdings Limited - Ordinary Shares trade on?
Connect Biopharma Holdings Limited - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Connect Biopharma Holdings Limited - Ordinary Shares?
The ticker symbol for Connect Biopharma Holdings Limited - Ordinary Shares is CNTB on the Nasdaq Stock Market
What is the current price of Connect Biopharma Holdings Limited - Ordinary Shares?
The current price of Connect Biopharma Holdings Limited - Ordinary Shares is 0.9484
When was Connect Biopharma Holdings Limited - Ordinary Shares last traded?
The last trade of Connect Biopharma Holdings Limited - Ordinary Shares was at 10/01/26 02:45 PM ET
What is the market capitalization of Connect Biopharma Holdings Limited - Ordinary Shares?
The market capitalization of Connect Biopharma Holdings Limited - Ordinary Shares is 52.20M
How many shares of Connect Biopharma Holdings Limited - Ordinary Shares are outstanding?
Connect Biopharma Holdings Limited - Ordinary Shares has 52M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.